Experience and lessons from surveillance and studies of the 2009 pandemic in Europe

References 

1. European Centre for Disease Control and Prevention Working Group . Influenza surveillance in a pandemic. ECDC; 2007;Available at: http://ecdc.europa.eu/en/Health_topics/Pandemic_Influenza/pdf/070801_Influenza_surveillance.pdf
2. World Health Organization . World Health Organization global influenza preparedness plan. Geneva: WHO; 2005;Available at: http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_5.pdf
3. European Commission . Communication from the Commission to the Council, the European Parliament, the European Economic and Social Committee and the Committee of the Regions on pandemic influenza preparedness and response planning in the European Community. EC; 2005;Available at: http://europa.eu.int/eur-lex/lex/LexUriServ/site/en/com/2005/com2005_0607en01.pdf
4. Mounier-Jack S, Coker RJ. How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet. 2006;367:1405–1411
   • Abstract
   • Full Text
   • Full-Text PDF (90 KB)
   • CrossRef
5. World Health Organization . Pandemic influenza preparedness and response. WHO guidance document. WHO; 2009;Available at: http://www.who.int/csr/disease/influenza/pipguidance2009/en/index.html
6. World Health Organization . Global surveillance during an influenza pandemic. WHO; 2009;Available at: http://www.who.int/csr/resources/publications/swineflu/surveillance/en/index.html
7. Nicoll A, Influenza Project Team , Ciancio B, de la Hoz KF, Kreidl P, Needham H, et al. Public health measures in an influenza pandemic–the importance of surveillance. Euro Surveill. 2007;12:E071101.4
8. European Centre for Disease Control and Prevention 2008.
9. European Centre for Disease Control and Prevention Pandemics of the 20th Century. ECDC; 2006;Available at: http://ecdc.europa.eu/en/Health_Topics/Pandemic_Influenza/stats.aspx
10. Lipsitch M, Riley S, Cauchemez S, Ghani AC, Ferguson NM. Managing and reducing uncertainty in an emerging influenza pandemic. N Engl J Med. 2009;361:112–115
    • CrossRef
11. Centers for Disease Control and Prevention . Update: novel influenza A(H1N1) virus infections–worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:453–458
12. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, et al. The global circulation of seasonal influenza A(H3N2) viruses. Science. 2008;320:340–346
    • CrossRef
13. Smith FB. The Russian influenza in the United Kingdom 1889–1894. Soc Hist Med. 1995;8:44–73
14. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12:9–14
    • MEDLINE
15. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, Schweiger B, et al. Oseltamivir-resistant influenza virus A(H1N1), Europe, 2007–08 season. Emerg Infect Dis. 2009;15:552–560
16. World Health Organization . WHO interim protocol: rapid operations to contain the initial emergence of pandemic influenza. WHO; 2007;Available at: http://www.who.int/csr/disease/avian_influenza/guidelines/draftprotocol/en/
17. World Health Organization . International Health Regulations. WHO. Available at: http://www.who.int/gb/ebwha/pdf_files/WHA58/WHA58_3-en.pdf2005;
18. European Parliament and Council . Decision No 2119/98/EC of the European Parliament and of the Council of 24 September 1998 setting up a network for the epidemiological surveillance and control of communicable diseases in the Community. OJ L 268. 1998;1–7
19. Kandun IN, Wibisono H, Sedyaningsih ER, Yusharmen , Hadisoedarsuno W, Purba W, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med. 2005;355:2186–2194
    • CrossRef
20. Health Protection Agency . HPA statement on possible transmission of oseltamivir resistant pandemic influenza A(H1N1). HPA; 2009;Available at: http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1258560561316?p=1231252394302
21. World Health Organization . Public health significance of virus mutation detected in Norway. WHO; 2009;Available at: http://www.who.int/csr/disease/swineflu/notes/briefing_20091120/en/index.html
22. Hayden FG. Antiviral resistance in influenza viruses. Implications for management and pandemic response. N Engl J Med. 2006;354:785–788
    • CrossRef
23. Jennings L, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis. 2008;8:650–658
    • Abstract
    • Full Text
    • Full-Text PDF (139 KB)
    • CrossRef
24. World Health Organization . WHO Guidelines on the use of vaccines and antivirals during influenza pandemics. WHO/CDS/CSR/RMD/2004.8. Geneva: WHO; 2004;Available at: http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_RMD_2004_8/en/
25. Cauchemez S, Ferguson NM, Wachtel C, Tegnell A, Saour G, Duncan B, et al. Closing schools during an influenza pandemic: a review. Lancet Infect Dis. 2009;9:473–481
    • Abstract
    • Full Text
    • Full-Text PDF (185 KB)
    • CrossRef
26. European Centre for Disease Control and Prevention . Interim scientific and public health briefing: updated 2008. Sharing influenza virus samples & influenza vaccine benefit sharing. ECDC; 2008;Available at: http://ecdc.europa.eu/en/files/pdf/Health_topics/ECDC_EU_Briefing_Influenza_Virus_Sharing_200812_Final_Dec_4th_long.pdf
27. McMenamin J, Phin N, Smyth B, Couzens Z, Nguyen-Van-Tam JS. Minimum dataset for confirmed human cases of influenza H5N1. Lancet. 2008;372:2022
    • Full Text
    • Full-Text PDF (167 KB)
    • CrossRef
28. Thompson WW, Moore MR, Weintraub E, Cheng PY, Jin X, Bridges CB, et al. Estimating influenza-associated deaths in the United States. Am J Public Health. 2009;99:S225–S230
    • CrossRef
29. World Health Organization . Considerations for assessing the severity of an influenza pandemic. Wkly Epidemiol Rec. 2009;84:197–202
30. United States Department of Health and Human Services and Centers for Disease Prevention and Control . Interim pre-pandemic planning guidance: community strategy for pandemic influenza mitigation in the United States. Available at: http://www.pandemicflu.gov/plan/community/community_mitigation.pdf2006;
31. World Health Organization . Transmission dynamics and impact of pandemic influenza A(H1N1) 2009 virus. Wkly Epidemiol Rec. 2009;84:481–484
32. Australian Government Ministry of Health and Aging . Influenza Surveillance Report No. 21 for the week ending 21 September 2009. Available at: 2009;http://www.healthemergency.gov.au/internet/healthemergency/publishing.nsf/Content/18D06BAC4644C98DCA25763E00823442/$File/ozflu-no19-2009.pdf
33. Baker MG, Wilson N, Huang QS, Paine S, Lopez L, Bandaranayake D, et al. Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill. 2009;14:19319
34. Centers for Disease Control and Prevention . CDC Estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States, April–October 17, 2009. CDC; 2009;Available at: http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm
35. Paget J, Marquet R, Meijer A, van de Velden K. Influenza activity in Europe during eight seasons (1999–2007): an evaluation of the indicators used to measure activity and an assessment of the timing, length and course of peak activity (spread) across Europe. BMC Infect Dis. 2007;7:141
    • CrossRef
36. European Centre for Disease Control and Prevention . ECDC concludes that vaccination of risk groups and healthcare workers should be further strengthened as seasonal influenza spreads across Europe. Press Release. Available at: http://ecdc.europa.eu/en/News_Media/Press_Releases/090108_pr_2.aspx2009;
37. European Centre for Disease Control and Prevention . Now casting and short-term forecasting during influenza pandemics. Report of focused developmental ECDC workshop, Stockholm, 29–30 November 2007. ECDC; 2008;Available at: http://www.ecdc.europa.eu/pdf/080409_meeting_pan.pdf
38. UK Department of Health . Scientific Pandemic Influenza Advisory Committee: Subgroup on Modelling. Modelling summary. 2008;Available at: http://www.advisorybodies.doh.gov.uk/spi/minutes/spi-m-modellingsummary.pdf
39. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature. 2006;442:448–452
    • CrossRef
40. Germann TC, Kadau K, Longini IM, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA. 2006;103:5935–5940
41. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007–lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill. 2009;14:19112
42. US Food and Drug Administration , HHS Public Health Service , FDA Centre for Drug Evaluation and Research . Post-marketing adverse events reports review of central nervous system/psychiatric disorders associated with the use of Tamiflu. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_09_01_Tamiflu%20AE%20Review%202006%20Redacted_D060309_092.pdf2006;
43. Sencer DJ, Miller JD. Reflections on the 1976 swine flu vaccination programme. Emerg Infect Dis. 2006;12:29–33
    • MEDLINE
44. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenza like illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009;169:382–388
    • CrossRef
45. Verstraeten T, DeStefano F, Chen RT, Miller E. Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. Expert Rev Vaccines. 2003;2:21–29
    • MEDLINE
    • CrossRef
46. Taylor B, Lingam R, Simmons A, Stowe J, Miller E, Andrews N. Autism and MMR vaccination in North London; no causal relationship. Mol Psychiatry. 2002;7(Suppl. 2):S7–S8
    • CrossRef
47. Kissling E, Valenciano M, Falcao J, Larrauri A, Widgren K, Pitigoi D, et al. ‘I-MOVE’ towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case–control study in Europe, 2008–9. Euro Surveill. 2009;14:19388
48. Centers for Disease Control and Prevention . Serum cross-reactive antibody response to a novel influenza A(H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58:521–524
49. European Centre for Disease Control and Prevention . Surveillance and studies in a pandemic: fourth meeting of the SSiaP working group. ECDC; 2009;Available at: http://www.ecdc.europa.eu/en/publications/Publications/0908_MER_Surveillance_and_Studies_in_a_Pandemic_Meeting_Report.pdf
50. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, et al. Pandemic potential of a strain of influenza A(H1N1): early findings. Science. 2009;324:1557–1561
    • CrossRef
51. European Centre for Disease Control and Prevention . Overview of surveillance of influenza 2009/2010 in the EU/EEA. ECDC; 2009;Available at: http://www.ecdc.europa.eu/en/publications/Publications/0909_TED_Overview_of_Surveillance_of_Influenza_2009-2010_in_EU-EEA.pdf
52. Health Protection Agency . Pandemic (H1N1) 2009 in England: an overview of initial epidemiological findings and implications for the second wave. HPA; 2009;Available at: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1258560552857
53. European Centre for Disease Control and Prevention . Pandemic risk assessment–version 6. ECDC; 2009;Available at: http://www.ecdc.europa.eu/en/healthtopics/Documents/0908_Influenza_AH1N1_Risk_Assessment.pdf
54. Swedish Presidency of the European Union . Summary from the Presidency meeting: pandemic influenza preparedness–lessons learned and next steps, Jönköping, 2–3 July 2009. Available at: http://www.se2009.eu/polopoly_fs/1.8266!menu/standard/file/Summary_draft_J%C3%B6nk%C3%B6ping_090705_final.pdf
55. Nicoll A, Coulombier D. Europe's initial experience with pandemic (H1N1) 2009–mitigation and delaying policies and practices. Euro Surveill. 2009;14:19279